228 related articles for article (PubMed ID: 37458162)
1. Children's Oncology Group's 2023 blueprint for research: Neuroblastoma.
Bagatell R; DuBois SG; Naranjo A; Belle J; Goldsmith KC; Park JR; Irwin MS;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30572. PubMed ID: 37458162
[TBL] [Abstract][Full Text] [Related]
2. Children's Oncology Group's 2023 blueprint for research: Germ cell tumors.
Bhuta R; Shah R; Gell JJ; Poynter JN; Bagrodia A; Dicken BJ; Pashankar F; Frazier AL; Shaikh F
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30562. PubMed ID: 37449938
[TBL] [Abstract][Full Text] [Related]
3. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
4. Children's Oncology Group's 2023 blueprint for research: Diversity and health disparities.
Winestone LE; Beauchemin MP; Bona K; Kahn J; Prasad P; Robles JM; Velez MC;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30592. PubMed ID: 37501542
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.
Irwin MS; Naranjo A; Zhang FF; Cohn SL; London WB; Gastier-Foster JM; Ramirez NC; Pfau R; Reshmi S; Wagner E; Nuchtern J; Asgharzadeh S; Shimada H; Maris JM; Bagatell R; Park JR; Hogarty MD
J Clin Oncol; 2021 Oct; 39(29):3229-3241. PubMed ID: 34319759
[TBL] [Abstract][Full Text] [Related]
7. Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma.
Balyasny S; Lee SM; Desai AV; Volchenboum SL; Naranjo A; Park JR; London WB; Cohn SL; Applebaum MA
JAMA Netw Open; 2021 Jul; 4(7):e2116248. PubMed ID: 34236408
[TBL] [Abstract][Full Text] [Related]
8. Children's Oncology Group's 2013 blueprint for research: neuroblastoma.
Park JR; Bagatell R; London WB; Maris JM; Cohn SL; Mattay KK; Hogarty M;
Pediatr Blood Cancer; 2013 Jun; 60(6):985-93. PubMed ID: 23255319
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD006301. PubMed ID: 26436598
[TBL] [Abstract][Full Text] [Related]
10. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
[TBL] [Abstract][Full Text] [Related]
11. Children's Oncology Group's 2023 blueprint for research: Behavioral science.
Embry L; Bingen K; Conklin HM; Hardy S; Jacola LM; Marchak JG; Paltin I; Pelletier W; Devine KA
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30557. PubMed ID: 37430416
[TBL] [Abstract][Full Text] [Related]
12. Children's Oncology Group's 2023 blueprint for research: Young investigators.
Esbenshade AJ; Kahalley LS; Wistinghausen B; Cash T; Baertschiger RM; Zarnegar-Lumley S; Green A; Dhall G;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30567. PubMed ID: 37438856
[TBL] [Abstract][Full Text] [Related]
13. Children's Oncology Group's 2023 blueprint for research: Epidemiology.
Lupo PJ; Marcotte EL; Scheurer ME; Poynter JN; Spector LG;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30566. PubMed ID: 37449937
[TBL] [Abstract][Full Text] [Related]
14. Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.
Owens C; Irwin M
Crit Rev Clin Lab Sci; 2012; 49(3):85-115. PubMed ID: 22646747
[TBL] [Abstract][Full Text] [Related]
15. Children's Oncology Group's 2023 blueprint for research: Soft tissue sarcomas.
Oberoi S; Crane JN; Haduong JH; Rudzinski ER; Wolden SL; Dasgupta R; Linardic CM; Weiss AR; Venkatramani R;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30556. PubMed ID: 37430436
[TBL] [Abstract][Full Text] [Related]
16. Neuroblastoma: clinical and biological approach to risk stratification and treatment.
Tolbert VP; Matthay KK
Cell Tissue Res; 2018 May; 372(2):195-209. PubMed ID: 29572647
[TBL] [Abstract][Full Text] [Related]
17. Children's Oncology Group's 2023 blueprint for research: Cancer control and supportive care.
Esbenshade AJ; Sung L; Brackett J; Dupuis LL; Fisher BT; Grimes A; Miller TP; Ullrich NJ; Dvorak CC;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30568. PubMed ID: 37430431
[TBL] [Abstract][Full Text] [Related]
18. Children's Oncology Group's 2013 blueprint for research: adolescent and young adult oncology.
Freyer DR; Felgenhauer J; Perentesis J;
Pediatr Blood Cancer; 2013 Jun; 60(6):1055-8. PubMed ID: 23424167
[TBL] [Abstract][Full Text] [Related]
19. Children's Oncology Group's 2023 blueprint for research: Surgery.
Gow KW; Lautz TB; Malek MM; Cost NG; Newman EA; Dasgupta R; Christison-Lagay ER; Tiao GM; Davidoff AM;
Pediatr Blood Cancer; 2024 Mar; 71(3):e30766. PubMed ID: 37950538
[TBL] [Abstract][Full Text] [Related]
20. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.
Twist CJ; Schmidt ML; Naranjo A; London WB; Tenney SC; Marachelian A; Shimada H; Collins MH; Esiashvili N; Adkins ES; Mattei P; Handler M; Katzenstein H; Attiyeh E; Hogarty MD; Gastier-Foster J; Wagner E; Matthay KK; Park JR; Maris JM; Cohn SL
J Clin Oncol; 2019 Dec; 37(34):3243-3255. PubMed ID: 31386611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
